Literature DB >> 24839003

Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines?

Bulent Gogebakan1, Recep Bayraktar, Ali Suner, Ozan Balakan, Mustafa Ulasli, Muzeyyen Izmirli, Serdar Oztuzcu, Celaletdin Camci.   

Abstract

Breast cancer (BC) is the most frequent cancer type in women, and the mortality rate is high especially in metastatic disease. Ion channels such as the transient receptor potential (TRP) channels correlate with malignant growth and cancer progression. Hence, some authors have suggested that the expression levels of TRP channels may be used as a marker in the diagnosis and predicting the prognosis of BC. Also, in some recent studies, targeting TRP channels are suggested as a novel treatment strategy in BC. The aim of this study was to investigate the effect of two Rho-kinase (ROCK) inhibitors, fasudil and Y-27632, on the expression levels of TRP channel genes in breast cancer cell lines (ZR-75-1, MCF7, and MDA-MB-231) and breast epithelial cell line (hTERT-HME1). The expression levels of TRP genes were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). We found that fasudil had reduced the TRPC1, TRPV2 expression levels in the ZR-75-1, MCF7, and MDA-MB-231 cell lines. On the other hand, fasudil and Y-27632 had reduced TRPM6 expression levels in all cell lines. Y-27632 increased the expression levels of TRPC7 in all cell lines. In conclusion, this is the first study demonstrating that the inhibition of ROCK pathway changes the expression levels of some TRP genes. Also, our study has firstly shown that the expression levels of the TRP genes which are suggested as a diagnostic and prognostic biomarker in BC, were changed with the treatment of fasudil and Y-27632.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839003     DOI: 10.1007/s13277-014-1752-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  Use and properties of ROCK-specific inhibitor Y-27632.

Authors:  S Narumiya; T Ishizaki; M Uehata
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Molecular mechanisms of TRP regulation in tumor growth and metastasis.

Authors:  Dimitra Gkika; Natalia Prevarskaya
Journal:  Biochim Biophys Acta       Date:  2008-12-06

3.  TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway.

Authors:  Xiaojing Meng; Chunqing Cai; Jiguo Wu; Shaoxi Cai; Changsheng Ye; Haiyang Chen; Zhengduo Yang; Hongqiang Zeng; Qiang Shen; Fei Zou
Journal:  Cancer Lett       Date:  2013-01-23       Impact factor: 8.679

Review 4.  Calcium signaling in cancer and vitamin D.

Authors:  Igor N Sergeev
Journal:  J Steroid Biochem Mol Biol       Date:  2005-08-02       Impact factor: 4.292

Review 5.  Ca2+-dependent transcriptional control of Ca2+ homeostasis.

Authors:  Jose R Naranjo; Britt Mellström
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 6.  Applications for ROCK kinase inhibition.

Authors:  Michael F Olson
Journal:  Curr Opin Cell Biol       Date:  2008-02-20       Impact factor: 8.382

7.  Enrichment map: a network-based method for gene-set enrichment visualization and interpretation.

Authors:  Daniele Merico; Ruth Isserlin; Oliver Stueker; Andrew Emili; Gary D Bader
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 8.  An introduction to TRP channels.

Authors:  I Scott Ramsey; Markus Delling; David E Clapham
Journal:  Annu Rev Physiol       Date:  2006       Impact factor: 19.318

9.  G protein-coupled estrogen receptor1 (GPER1) may mediate Rho-kinase (ROCK-2) up-regulation in coronary endothelial cells.

Authors:  A H Kurt; R N Tiftik; I Un; S Ulker; K Buyukafsar
Journal:  Endocr Regul       Date:  2013-04

Review 10.  Breast cancer as a systemic disease: a view of metastasis.

Authors:  A J Redig; S S McAllister
Journal:  J Intern Med       Date:  2013-08       Impact factor: 8.989

View more
  5 in total

1.  Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin.

Authors:  Souleymane Abdoul-Azize; Catherine Buquet; Hong Li; Jean-Michel Picquenot; Jean-Pierre Vannier
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

2.  TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.

Authors:  Mohamad Elbaz; Dinesh Ahirwar; Zhang Xiaoli; Xinyu Zhou; Maryam Lustberg; Mohd W Nasser; Konstantin Shilo; Ramesh K Ganju
Journal:  Oncotarget       Date:  2016-05-27

3.  Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation.

Authors:  Cécile Pétigny; Audrey-Ann Dumont; Hugo Giguère; Audrey Collette; Brian J Holleran; Mircea Iftinca; Christophe Altier; Élie Besserer-Offroy; Mannix Auger-Messier; Richard Leduc
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 6.208

4.  Y-27632 Increases Sensitivity of PANC-1 Cells to EGCG in Regulating Cell Proliferation and Migration.

Authors:  Xing Liu; Yongyi Bi
Journal:  Med Sci Monit       Date:  2016-10-03

5.  Construction and Validation of a Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer.

Authors:  Shilong Li; Zongxian Zhao; Huaxiang Yang; Daohan Wang; Weilin Sun; Shuliang Li; Zhaoxiong Zhang; Weihua Fu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.